WO2010037892A1 - Composition comprenant de la silibinine à des concentrations déterminées et préparation combinée comprenant de la silibinine et un inhibiteur de la voie pi3k/akt pour le traitement du cancer - Google Patents
Composition comprenant de la silibinine à des concentrations déterminées et préparation combinée comprenant de la silibinine et un inhibiteur de la voie pi3k/akt pour le traitement du cancer Download PDFInfo
- Publication number
- WO2010037892A1 WO2010037892A1 PCT/ES2009/070415 ES2009070415W WO2010037892A1 WO 2010037892 A1 WO2010037892 A1 WO 2010037892A1 ES 2009070415 W ES2009070415 W ES 2009070415W WO 2010037892 A1 WO2010037892 A1 WO 2010037892A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- silibinin
- cancer
- akt
- hif
- cells
- Prior art date
Links
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 title claims abstract description 194
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 title claims abstract description 190
- 229950000628 silibinin Drugs 0.000 title claims abstract description 188
- 235000014899 silybin Nutrition 0.000 title claims abstract description 188
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 91
- 201000011510 cancer Diseases 0.000 title claims abstract description 72
- 238000011282 treatment Methods 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 230000037361 pathway Effects 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000003112 inhibitor Substances 0.000 title claims abstract description 23
- 108091007960 PI3Ks Proteins 0.000 claims abstract description 37
- 210000002966 serum Anatomy 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 20
- 239000003197 protein kinase B inhibitor Substances 0.000 claims abstract description 17
- 229940126638 Akt inhibitor Drugs 0.000 claims abstract description 15
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims abstract 6
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 229940002612 prodrug Drugs 0.000 claims description 12
- 239000000651 prodrug Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 11
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 11
- 201000010881 cervical cancer Diseases 0.000 claims description 11
- 238000001802 infusion Methods 0.000 claims description 10
- -1 TCN Chemical compound 0.000 claims description 8
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 7
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims description 7
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims description 4
- IWCQHVUQEFDRIW-UHFFFAOYSA-N 3-[1-[[4-(6-phenyl-8H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one Chemical compound O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(cc2)-c2[nH]c3cc4ncnc4cc3nc2-c2ccccc2)CC1 IWCQHVUQEFDRIW-UHFFFAOYSA-N 0.000 claims description 3
- HOGVTUZUJGHKPL-UHFFFAOYSA-N LSM-1546 Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3C1OC(CO)C(O)C1O HOGVTUZUJGHKPL-UHFFFAOYSA-N 0.000 claims description 3
- XSYODYDCSYFRRB-KTTODTSBSA-N [(2r)-2-methoxy-3-octadecoxypropyl] (2,3,4-trihydroxycyclohexyl) hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP(O)(=O)OC1CCC(O)C(O)C1O XSYODYDCSYFRRB-KTTODTSBSA-N 0.000 claims description 3
- 229950003873 triciribine Drugs 0.000 claims description 3
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 120
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 83
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 81
- 206010021143 Hypoxia Diseases 0.000 description 70
- 230000007954 hypoxia Effects 0.000 description 50
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 33
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 33
- 230000000694 effects Effects 0.000 description 32
- 102000038030 PI3Ks Human genes 0.000 description 31
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 31
- 230000005764 inhibitory process Effects 0.000 description 29
- 238000009825 accumulation Methods 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 230000001146 hypoxic effect Effects 0.000 description 19
- 230000007959 normoxia Effects 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 15
- 230000004913 activation Effects 0.000 description 15
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 14
- 238000003119 immunoblot Methods 0.000 description 14
- 238000011534 incubation Methods 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 230000026731 phosphorylation Effects 0.000 description 13
- 238000006366 phosphorylation reaction Methods 0.000 description 13
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 12
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 12
- 229960002930 sirolimus Drugs 0.000 description 12
- 230000014616 translation Effects 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 108050000946 Eukaryotic translation initiation factor 4E-binding protein 1 Proteins 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000011664 signaling Effects 0.000 description 9
- 102100022466 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 description 8
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 8
- 108010002974 benzyloxycarbonylleucyl-leucyl-leucine aldehyde Proteins 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 7
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 7
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 7
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 7
- 102000003861 Ribosomal protein S6 Human genes 0.000 description 7
- 108090000221 Ribosomal protein S6 Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 102100030907 Aryl hydrocarbon receptor nuclear translocator Human genes 0.000 description 6
- 101000793115 Homo sapiens Aryl hydrocarbon receptor nuclear translocator Proteins 0.000 description 6
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- BNJOZDZCRHCODO-UHFFFAOYSA-N dimethyloxalylglycine Chemical compound COC(=O)CNC(=O)C(=O)OC BNJOZDZCRHCODO-UHFFFAOYSA-N 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229940124302 mTOR inhibitor Drugs 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000033444 hydroxylation Effects 0.000 description 4
- 238000005805 hydroxylation reaction Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 241001506137 Rapa Species 0.000 description 3
- 108010052090 Renilla Luciferases Proteins 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000030609 dephosphorylation Effects 0.000 description 3
- 238000006209 dephosphorylation reaction Methods 0.000 description 3
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000020874 response to hypoxia Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- SBPIDKODQVLBGV-UHFFFAOYSA-N 1h-imidazole;pyridine Chemical compound C1=CNC=N1.C1=CC=NC=C1 SBPIDKODQVLBGV-UHFFFAOYSA-N 0.000 description 2
- KDMGQPNVTKUNHV-UHFFFAOYSA-N 3,5,7-trihydroxy-2-[3-(3-hydroxy-4-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C1C(CO)OC2=CC=C(C3C(C(=O)C4=C(O)C=C(O)C=C4O3)O)C=C2O1 KDMGQPNVTKUNHV-UHFFFAOYSA-N 0.000 description 2
- 206010060999 Benign neoplasm Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000000274 Carcinosarcoma Diseases 0.000 description 2
- 102000005233 Eukaryotic Initiation Factor-4E Human genes 0.000 description 2
- 108060002636 Eukaryotic Initiation Factor-4E Proteins 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 2
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 2
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 2
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 108010029031 Regulatory-Associated Protein of mTOR Proteins 0.000 description 2
- 102100040969 Regulatory-associated protein of mTOR Human genes 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- 244000272459 Silybum marianum Species 0.000 description 2
- 235000010841 Silybum marianum Nutrition 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 102000049131 human HIF1A Human genes 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000013930 proline Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229960004245 silymarin Drugs 0.000 description 2
- 235000017700 silymarin Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000002229 urogenital system Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008968 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101001077600 Homo sapiens Insulin receptor substrate 2 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 1
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 1
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100087591 Mus musculus Rictor gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 208000025618 Paget disease of nipple Diseases 0.000 description 1
- 208000024024 Paget disease of the nipple Diseases 0.000 description 1
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010036040 Polychromasia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102000046941 Rapamycin-Insensitive Companion of mTOR Human genes 0.000 description 1
- 108700019586 Rapamycin-Insensitive Companion of mTOR Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000001929 anti-hepatotoxic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 201000007327 bone benign neoplasm Diseases 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000003401 eosinophilic granuloma Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000047486 human GAPDH Human genes 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000008481 normal tissue growth Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- SEBFKMXJBCUCAI-DBMPWETRSA-N silybin Chemical compound C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-DBMPWETRSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030829 thyroid gland adenocarcinoma Diseases 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 102100035070 von Hippel-Lindau disease tumor suppressor Human genes 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Definitions
- the present invention is within the field of medicine, and refers to a composition comprising silibinin at certain concentrations, and to said composition that also comprises an Akt inhibitor, for the treatment of cancer.
- hypoxia is a common characteristic of most solid tumors. As the tumor cells proliferate, the demand for nutrients and oxygen grows to the point where the diffusion of oxygen from the blood vessels becomes limiting, resulting in hypoxia. Cancer cells adapt to this hypoxic environment through the activation of a number of cell pathways that stimulate glycolysis, proliferation, over-regulation of numerous survival factors, and neovascularization (angiogenesis). These processes provide the tumor with sufficient energy and a blood supplement to allow growth under hypoxic conditions.
- HIF-1 hypoxia-inducible factor 1
- HIF-1 hypoxia-inducible factor 1
- HIF-1 ⁇ hypoxia-inducible factor 1
- HIF-1 ⁇ hypoxia-inducible factor 1
- HIF-1 ⁇ is rapidly and continuously degraded by the ubiquitin-proteasome system after its binding to von Hippel's protein.
- HIF-1 ⁇ Lindau (pVHL), in a process that depends on the hydroxylation of proline residues 402 and 564 by a family of enzymes known as prolyl-4-hydroxylases that are dependent on O2, iron and oxoglutarate.
- prolyl-4-hydroxylases that are dependent on O2, iron and oxoglutarate.
- the hydroxylation of HIF-1 ⁇ is inhibited, which leads to an increase in the stability of HIF-1 ⁇ .
- prolyl hydroxylases in hypoxia is recognized as the primary mechanism of the accumulation of HIF-1 ⁇ , it is evident that the expression of HIF-1 ⁇ also depends on its de novo synthesis rate.
- Some growth factors, cytokines, and other signaling molecules can stimulate the synthesis of HIF-1 ⁇ protein through the activation of the phosphatidylinositol-3-kinase (PI3K) / Akt / mTOR (mammalian target of rapamycin) pathway.
- mTOR regulates the translation of proteins containing sequences 5 '-terminal TOP through the increase of the phosphorylation of p70S6K effectors (ribosomal protein S6 kinase) and rpS6 (ribosomal protein S6), whichever results in the increase of the translation of mRNAs (oligopyr ⁇ midine tract) in its 5 ' -UTR.
- mTOR also phosphorylates the 4E-BP1 factor (eukaryotic translation initiation factor 4E-binding protein-1), which results in the activation of elF4E (eukaryotic initiation factor 4E) and induces cap-dependent translation. Recent data suggest that the activity of mTOR is necessary for the expression of HIF-1 ⁇ regardless of the conditions of cellular oxygenation.
- 4E-BP1 factor eukaryotic translation initiation factor 4E-binding protein-1
- Silibinin is an antioxidant flavonoid isolated from Silybum marianum L. Gaertn., which is used clinically for its hepatoprotective properties and as an antihepatotoxic agent for the treatment of various liver diseases, also being sold as a dietary supplement. Recently, its preventive, antiproliferative and pro-apoptotic effects have been proven in several cancer cells, mainly in skin, breast, lung, colon, pancreas and prostate cancer.
- silibinin inhibits angiogenesis through the downward regulation of the Akt and NF- ⁇ B pathways (Mallikarjuna et al., 2004. Cancer Res. 64: 6349-6356).
- the molecular mechanism by which silibinin exerts its antitumor effects is not known exactly.
- mTOR protein kinase can form two multiproteic complexes that regulate different aspects of mTOR signaling: the mTOR 1 Complex (mTORCI) and the mTOR 2 Complex (mTORC2).
- mTORCI mTOR 1 Complex
- mTORC2 mTOR 2 Complex
- the mTORCI complex is composed of mTOR, raptor (regulatory-associated protein of mTOR), and ml_ST8, and regulates cell growth and proliferation by modulating processes such as ribosomal biogenesis and protein translation through its effectors p70S6K, rpS6 and 4E-BP1.
- the mTORC2 complex contains mTOR, rictor
- Akt PI3K / Akt, while mTORCI inhibition would activate Akt through the negative feed-back produced by p70S6K. It is accepted that rapamycin and its analogs are universal inhibitors of mTORCI (and p70S6K), while they are inhibitors of mTORC2 depending on the cell type, and so on Akt (Sabatini 2006. Nat Rev Cancer 6: 729-734).
- the tumor cells in which the inhibition of mTOR results in the deactivation of Akt would be those in which a rapamycin-sensitive mTORC2 complex is expressed, while the cells in which Akt is activated or unaffected by mTOR inhibitors they could be those that express a rapamycin insensitive mTORC2 complex, as demonstrated in HeLa cells (Sarbassov et al., 2006. Mol CeII 22: 159-68).
- silibinin both to treat prostate cancer and other types of cancer
- silibilin is marketed in the form of 150 mg capsules, or as a lyophilized injectable solution containing the equivalent of 350 mg of silibinin.
- Studies in mice have shown that administering 2 g of silibinin per kg of body weight orally reaches up to 160 ⁇ M of silibinin in plasma (Agarwal et al., 2003. Oncogene 22, 8271-8282).
- the recommended dose for injectable administration is 20 mg of silibinin per kg of body weight and day, divided into 4 IV (intravenous) infusions of 2 hours each, and with 4 hours of interval between them, controlling the balance of liquids In each infusion, therefore, 5 mg of silibinin per kg of body weight will be administered.
- one vial 350 mg of silibinin
- the contents of the vial are dissolved in 35 ml of the infusion solution to be administered (0.9% sodium chloride solution or 5% glucose) and the amount of reconstituted solution (1 ml «is added 10 mg silibinin), necessary, depending on the weight of the patient, the rest of the saline or glucose.
- treatment with silibinin in most types of cancer will be more effective if high doses of the same are administered to the patient, which allow reaching concentrations in cells greater than 250 ⁇ M, and even more preferably, of 500 ⁇ M, in serum.
- a first aspect of the invention refers to the use of a pharmaceutical composition, hereinafter the first composition of the invention, comprising as active ingredient silibinin, a pharmaceutically acceptable salt, or a prodrug, derivative or analog thereof, for Ia elaboration of a medicine for the treatment of cancer, where silibinin is in the proportion necessary to reach serum concentrations (cellular) equal to or greater than 250 ⁇ M, or alternatively, to a pharmaceutical composition comprising as active ingredient silibinin, a pharmaceutically acceptable salt, or a prodrug, derivative or analogue thereof in the proportion necessary to reach serum concentrations (cellular) equal to or greater than 250 ⁇ M, for use in the treatment of cancer.
- silibinin concentrations are kept substantially constant, the Cmin (minimum concentration) being in serum of at least 250 ⁇ M.
- Silibinin (INN International Nonprop ⁇ etary ⁇ ame), also known as silibin or silibinin, is the main active constituent of silymarin, the mixture of flavolignans extracted from Silybum marianum. They have as CAS number 22888-70-6, and as chemical formula IUPAC (International Union of Puré and Applied Chemistry) 3,5,7-trihydroxy-2- (3- (3-hydroxy-4- methoxyphenyl) -2- ( hydroxymethyl) -2,3 dihydrobenzo [b] [1,4] dioxin-6-yl) chroman-4- one.
- silibinin herein, it is understood both the silibinin itself and any of its derivatives, salts, prodrugs, or the like, or any combination thereof.
- active substance means any component that potentially provides a pharmacological activity or other different effect on the diagnosis, cure, mitigation, treatment, or prevention of a disease, or that affects the structure or function of the body of man or other animals.
- the term includes those components that promote a chemical change in the preparation of the drug and are present therein in a modified form provided that provides the specific activity or effect.
- derivative includes both pharmaceutically acceptable compounds, and pharmaceutically unacceptable derivatives, since these may be useful in
- prodrugs of silibinin include any compound derived from silibinin, for example, esters, including carboxylic acid esters, amino acid esters, phosphate esters, metal salt sulphonate esters, etc., carbamates, amides , etc., which, when administered to an individual, is capable of providing, directly or indirectly, said compound of formula (I) in said individual.
- said derivative is a compound that increases the bioavailability of the compound of formula (I) when administered to an individual or that enhances the release of the compound of formula (I) in a biological compartment.
- the nature of said derivative is not critical, as long as it can be administered to an individual and provides the compound of formula (I) in a biological compartment of an individual.
- the preparation of said prodrug can be carried out by conventional methods known to those skilled in the art.
- substantially constant with respect to the serum concentration of the active ingredient (silibilin, pharmaceutically acceptable salts, derivatives or analogs, or any combination thereof) means that the serum profile after the administration of the formulation does not essentially have values substantial peak. This can also be expressed mathematically in relation to the "fluctuation index" (Fl) for the serum concentration of the active substance (not bound) (or the sum of the active ingredients when applicable), where the Fl fluctuation index is calculated how:
- Cmax and Cmin are the maximum and minimum concentrations, respectively, of active ingredient
- AUC_ is the area under the serum concentration profile (concentration versus time curve)
- ⁇ is the length of the dose interval throughout the period ⁇ .
- the Cmin would be 250 ⁇ M, and even more preferably, 500 ⁇ M.
- Ways to achieve substantially constant concentrations of the active ingredient in serum are known in the state of the art, such as, but not limited to, by the use of controlled release pharmaceutical forms.
- the formulation of the present invention is not restricted to any particular type of formulation. For this reason, the embodiment of the present invention can be used various types of controlled or sustained release formulations, such as, for example, osmotic tablets, gelatinous matrix tablets, coated pellets, etc.
- a preferred embodiment of this aspect of the invention refers to the use of a pharmaceutical composition comprising as active ingredient silibinin, a pharmaceutically acceptable salt, or a prodrug, derivative or analogous thereof, for the preparation of a medicament for the treatment of cancer.
- silibinin is in the proportion necessary to reach serum concentrations (cellular) equal to or greater than 500 ⁇ M
- a pharmaceutical composition comprising as active ingredient silibinin, a pharmaceutically acceptable salt, or a prodrug, derivative or analog thereof in the proportion necessary to reach serum concentrations (cellular) equal to or greater than 500 ⁇ M, for use in the treatment of cancer.
- silibinin concentrations are kept substantially constant, the serum Cmin being at least 500 ⁇ M.
- silibinin is found as silibinin-C-2 ', 3-disodium dihydrogen succinate.
- the pharmaceutical composition also comprises a pharmaceutically acceptable carrier.
- the cancer is selected from the list comprising: cervical cancer, gastrointestinal cancer and liver cancer.
- silibinin necessary to reach said cellular concentrations will depend on the formulation of the drug, and on the pharmaceutically accepted vehicles that allow an adequate release of silibinin. Suitable formulation methods are known in the state of the art. Methods of extrapolation of drug concentrations In vitro serum values in vivo are also known in the state of the art, such as, but not limited to, those described in Gülden & Sebet 2003. Toxicology 189: 211-222.
- the medicament comprises the necessary concentration of silibinin to reach serum concentrations equal to or greater than 500 ⁇ M, which, following the above reasoning, would be equivalent to 20.82 mg / ml in 35 ml, so that the pharmaceutical composition must have values of Silibilin greater than 730 mg.
- Other methods of calculating the necessary concentration of silibinin to achieve serum concentrations greater than 250 ⁇ M, and even more preferably, concentrations greater than 500 ⁇ M are known and well documented in the state of the art, and as said, will depend on The formulation used, the route of administration, and other factors, such as the weight and age of the patient.
- the recommended dose for injectable administration is greater than 40 mg of silibinin per kg of body weight and day, divided into 4 IV (intravenous) infusions of 2 hours each, and with an interval of 4 hours between them, controlling the balance of liquids.
- IV intravenous
- more than 10 mg of silibinin per kg of body weight will be administered, thus reaching serum concentrations of approximately 500 ⁇ M.
- Another alternative would be the elaboration of controlled release forms that maintain the concentrations of the active substance. (silibilin, pharmaceutically acceptable salts, derivatives or analogs, or any combination thereof) in serum substantially constant and equal to or greater than 250 ⁇ M, and even more preferably, substantially constant and equal to or greater than 500 ⁇ M.
- the route of administration of the injectable solution can be, without limitation, intravenous, but preferably, it is administered by direct injection into the tumor, since it allows the therapeutic effect to be concentrated at the level of the affected tissues, or by any form of known controlled release. in the state of the art that allows to maintain in serum the concentrations of the active principle described herein.
- Said controlled release pharmaceutical form can also be located or implanted in the area of interest (in the tumor).
- Another aspect of the invention relates to a vial for infusion with lyophilized product comprising silibinin-C-2 ', 3-dihydrogen disodium succinate in values of approximately 550 mg (551, 15 mg of silibinin-C-2', 3- disodium dihydrogen succinate, equivalent to 365 mg of silibinin (INN),
- the lyophilized product infusion vial comprising silibinin-C-2 ', 3-dihydrogen disodium succinate in values of approximately 1100 mg (1102, 3 mg of silibinin-C-2 ', 3-dihydrogen disodium succinate, equivalent to 730 mg of silibinin (INN).
- the present invention provides a useful treatment for cancer, especially for those types of cancer in which silibinin indirectly activates the PI3K / Akt pathway, by administering silibinin and an inhibitor of the PI3K / Akt pathway.
- silibinin inhibits the accumulation of hypoxia-induced HIF-1 ⁇ in several cell lines.
- silibinin represses the activity of mTOR and its effectors p70S6K, rpS6 and 4E-BP1, increasing the phosphorylation of Akt, and that the combined use of silibinin with inhibitors of the PI3K / Akt pathway has a synergistic effect in the treatment of certain types of cancer, by preventing Ia activation of PI3K / Akt that produces silibinin in certain cell types.
- compositions comprising silibinin and an inhibitor of the PI3K / Akt pathway are more useful in those types of cancer in which silibinin produces an activation of the PI3K / Akt pathway.
- another aspect of the invention relates to a composition, hereinafter second composition of the invention, comprising silibinin and an inhibitor of the PI3K / Akt pathway.
- Another aspect of the invention refers to the use of the composition of the invention as a medicine, or alternatively, to the second composition of the invention for use as a medicine.
- Silibinin (INN International Nonproprietary ⁇ ame), also known as silibinin, is the main active constituent of silymarin, the mixture of flavolignans extracted from Silybum mar ⁇ anum. They have the chemical formula IUPAC (International Union of Puré and Applied Chemistry) 3,5,7-trihydroxy-2- (3- (3-hydroxy-4-methoxyphenyl) -2- (hydroxymethyl) -2,3 dihydrobenzo [b] [1, 4] dioxin-6-yl) chroman-4-one.
- IUPAC International Union of Puré and Applied Chemistry
- the PI3K / Akt pathway has been widely studied and has been recognized as a promising target for anticancer therapies since its activation is a key cellular event during tumorigenesis. Once the PI3K and Akt kinases have been activated under apoptotic stress, signals are translated into a series of downstream regulators.
- Akt inhibitors include LY294002 (CAS 154447-36-6) and Wortmannin (CAS 19545-26-7), and among Akt inhibitors, Triciribine (API-2, NSC-154020, TCN, Akt inhibitor V ; CAS 35943-35-2), A-443654 (imidazole-pyridine based), KP372-1, Akt Inhibitor Il (SH-5), Akt Inhibitor III (SH-6), Akt Inhibitor IV (CAS 681281-88- 9), Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 (hydrated salt of 1,3-Dihydro-1- trifluoroacetate (1 - ((4- (6-phenyl-1 H-imidazo [4,5- g] quinoxalin-7-yl) phenyl) methyl) -4-piperidinyl) -2H-benzimidazol-2-one), Akt Inhibitor X (CAS 925681-41-0).
- the Akt inhibitor is selected from the list comprising: LY294002, Wortmannin, Triciribine (API-2, NSC-154020, TCN, Akt inhibitor V), A-443654 (imidazole-pyridine based), KP372-1, Akt Inhibitor Il (SH-5), Akt Inhibitor III (SH-6), Akt Inhibitor IV, Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2, Akt Inhibitor X
- the PI3K / Akt pathway inhibitor is LY294002.
- silibinin has an mTOR inhibitory effect, useful in the treatment of cancer, and at the same time inhibitors of the activation of the PI3K / Akt pathway are useful in those types of cancer in which silibinin, at Like other mTOR inhibitors, they activate this pathway.
- the combined use of silibinin with the PI3K / Akt inhibitor employed (LY294002) gives rise to a synergistic effect on certain tumor cell lines.
- composition of the invention for the preparation of a medicament for the treatment of cancer.
- the types of cancer are selected from the list comprising: cervical cancer, cancer gastrointestinal or liver cancer.
- the cancer is cervical cancer.
- Another aspect of the invention relates to a combined preparation of at least silibinin and an inhibitor of the PI3K / Akt pathway, from now on combined preparation of the invention, for its separate, simultaneous or sequential use in the treatment of Cancer.
- silibinin acts as an anticancer by inhibiting mTOR, and since the function of mTOR and its regulation by the PI3K / Akt pathway is a specific tumor, the treatment of silibinin cancer sometimes activates the pathway PI3K / Akt. The activation of
- the PI3K / Akt pathway is necessary for cell differentiation, and probably has a great physiological relevance, since it couples vital processes such as cell differentiation and survival.
- the combination of silibinin with a PI3K / Akt inhibitor synergistically increases the response, as shown in the examples of the invention, not representing a mere aggregate of known agents, but a new combination that provides a new effective treatment. against cancer
- Silibinin and the PI3K / Akt inhibitor could be administered to a patient separately, simultaneously or sequentially, depending on the most appropriate administration schedule for each case.
- Said combined preparation of silibinin and an inhibitor of the PI3K / Akt route separately, simultaneously or sequentially would be useful in the preparation of a medicament for the treatment of cancer.
- the term "combined preparation” or also called “juxtaposition”, herein means that the components of the combined preparation need not be present as a union, for example in a composition, in order to be available for separate application or sequential.
- the expression “juxtaposed” implies that it is not necessarily a true combination, in view of the physical separation of the components.
- the combined preparation of the invention is used for the treatment of a series of cancers that are selected from the list comprising: cervical cancer, gastrointestinal cancer and liver cancer.
- the cancer is cervical cancer.
- cancer means a set of diseases in which the body produces an excess of malignant cells (also known as cancer or cancer), with typical behavioral and uncontrolled growth traits (growth and division beyond the limits normal, invasion of surrounding tissue and sometimes metastasis). It comprises any disease of an organ or tissue in a mammal, preferably man, characterized by a poorly controlled, or uncontrolled, multiplication of normal or abnormal cells in said tissue, and their effect on the entire body.
- cancer within this definition, includes benign neoplasms, dysplasias, hyperplasias, as well as neoplasms that show metastases, or any other transformation such as, for example, leukoplasias that often precede the outbreak of cancer.
- Cancer cells and tissues are cancerous when they grow and replicate more quickly than normal, moving or dispersing in the surrounding healthy tissue or any other body tissue, which is known as metastasis, assumes forms and abnormal sizes, shows changes in its nucleocytoplasmic ratio, nuclear polychromasia, and finally ceases. Cancer cells and tissues can affect the body as a whole causing paraneoplastic syndromes, or if cancer occurs in a vital organ or tissue, its normal function being interrupted or damaged, with possible fatal results. The final result of the evolution of a cancer that involves a vital organ, either primary or metastatic, is the death of the affected mammal. The cancer tends to spread, and its degree of extension is normally related to changes in the survival of the disease.
- the cancer is in one of three growth stages: early or localized, when the tumor is still confined in the tissue of origin, or in its primary location; direct extension, when the cancer cells of the tumor have invaded adjacent tissue or have spread only to regional lymph nodes; or metastasis, when cancer cells have migrated to distant parts of the body from the primary location, through the circulatory or lymphatic system, and has been established in secondary locations.
- a cancer is malignant because of its tendency to cause death if it is not treated.
- Benign tumors usually do not cause death, although they can do so if they interfere with the normal function of the body due to its characteristics or location, size or paraneoplastic effects.
- the malignant tumors fall within the definition of cancer within the scope of this definition as well.
- cancer cells divide at a higher rate than normal cells, but the distinction between the growth of normal and cancerous tissues is not so much that cell division is much faster, such as partial or complete loss of stopping growth and differentiate into a useful and limited tissue, of the type that characterizes the functional balance of normal tissue growth.
- the cancerous tissue can express certain receptor molecules and are probably influenced by susceptibility and immunity, and it is known that certain prostate and breast cancers, for example, depend on certain hormones.
- the term "cancer” herein is not simply limited to benign neoplasms, but also includes other benign or malignant neoplasms such as: 1) Carcinoma, 2) Sarcoma, 3) Carcinosarcoma, 4) Blood-forming tissue cancers, 5) tumors of nerve tissues, including the brain, 6) cancer of skin cells.
- Carcinosarcoma occurs in the epithelial tissues, which cover the external face of the body (the skin) and the mucous membranes and the internal cavity of the structure of the organs, such as the breasts, the lung, the digestive and gastrointestinal tract, the glands endocrine, and the genitourinary system.
- Ductal or glandular elements may persist in epithelial tumors, as well as in adenocarcinomas, such as thyroid adenocarcinoma, gastric adenocarcinoma, uterine adenocarcinoma.
- Cancers of the epithelium of paved cells of the skin and certain mucous membranes can be called squamous cell carcinoma of the respective tissues, and are also within the definition of cancer in this memory.
- Sarcoma develops in connective tissues, including fibrous, adipose tissue, muscle, blood vessels, bone, and cartilage such as osteogenic sarcoma, liposarcoma, fibrosarcoma, and synovial sarcoma.
- Carcionosarcomas develop in both epithelial and connective tissue.
- the cancer can be primary or secondary. Primary indicates that The cancer has originated in the tissue that has been found, rather than having been established after metastasis from another region.
- Cancer and tumor diseases can also be benign or malignant, and can affect the anatomical structures of a mammalian body. For example, but without limiting our, they can be:
- endocrine and exocrine glands such as thyroid, parathyroid, pituitary, adrenal glands, salivary glands, pancreas.
- breast such as benign and malignant tumors in the mammary glands of both men and women, mammary ducts, adenocarcinoma, medullary carcinoma, carcinoma carcinoma. Paget's disease of the nipple, inflammatory carcinoma of young women, ...
- Bone, and its connective and supportive tissues such as malignant or benign bone tumor, for example, osteogenic malignant sarcoma, benign osteoma, cartilage tumors; such as malignant chondrosarcoma or benign chondroma; Bone marrow tumors, such as malignant myeloma, or benign eosinophilic granuloma, as well as metastatic tumors of bone tissues in other locations of the body,
- pancreas such as ductal carcinoma of the pancreas
- Lymphatic tissue such as lymphomas and other tumors of lymphoid origin
- XV Lymphatic tissue
- XVII primary and secondary cancer of the lymph nodes
- XVIII The tongue and bone structures of the palate and sinuses
- XXI The smooth or skeletal muscle, including its ligaments and membranes
- XXII The peripheral, autonomous and central nervous system, including the cerebellum
- compositions of the present invention and the combined preparation can be formulated for administration to an animal, and more preferably to a mammal, including man, in a variety of ways known in the state of the art.
- they can be, without limitation, in sterile aqueous solution or in biological fluids, such as serum.
- Aqueous solutions may be buffered or unbuffered and have additional active or inactive components. Additional components include salts to modulate the ionic strength, preservatives including, but not limited to, antimicrobial agents, antioxidants, chelants, and the like, and nutrients including glucose, dextrose, vitamins and minerals.
- the compositions can be prepared for administration in solid form.
- compositions can be combined with various vehicles or excipients inert, including but not limited to; binders such as microcrystalline cellulose, gum tragacanth, or gelatin; excipients such as starch or lactose; dispersing agents such as alginic acid or corn starch; lubricants such as magnesium stearate, glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; or flavoring agents such as peppermint or methyl salicylate.
- binders such as microcrystalline cellulose, gum tragacanth, or gelatin
- excipients such as starch or lactose
- dispersing agents such as alginic acid or corn starch
- lubricants such as magnesium stearate, glidants such as colloidal silicon dioxide
- sweetening agents such as sucrose or saccharin
- flavoring agents such as peppermint or methyl salicylate.
- compositions or preparations and / or their formulations may be administered to an animal, including a mammal and, therefore, to man, in a variety of ways, including, but not limited to, intraperitoneal, intravenous, intramuscular, subcutaneous, intracecal, intraventricular, oral, enteral, parenteral, intranasal or dermal.
- the dosage to obtain a therapeutically effective amount depends on a variety of factors, such as, for example, the age, weight, sex, tolerance, ... of the mammal.
- the expression "therapeutically effective amount” refers to the amount of silibinin, prodrugs, derivatives or analogs of silibinin that produce the desired effect and, in general, will be determined, among other causes, by the characteristics typical of said prodrugs, derivatives or analogs and the therapeutic effect to be achieved.
- the pharmaceutically acceptable adjuvants and vehicles that can be used in said compositions are the vehicles known to those skilled in the art.
- Fig. 1 Silibinin inhibits the accumulation of hypoxia-induced HIF-1 ⁇ protein and transcriptional activation of HIF-1.
- A. The HeLa and Hep3B tumor cells were exposed to hypoxic conditions (2% O2) for the times indicated in the absence or presence of silibinin (SiIi, 500 ⁇ mol / L). Protein levels of HIF-1 ⁇ , HIF-1 ⁇ and actin were detected by immunoblot from total cell extracts as described in materials and methods.
- B Hep3B cells were treated for 4 h in normoxia (21% O2, lane 1), hypoxia (2% O2), or with the hypoxia-mimetic agent DMOG (1 mmol / L) in the presence of silibinin in the indicated concentrations, or with the vehicle (0).
- HeLa cells were exposed to the indicated hypoxia levels ([O 2 ], 6, 3, 1 and 0.1%) for 4 h in the absence or presence of silibinin (SiIi, 500 ⁇ mol / L).
- the levels of the HIF-1 ⁇ and actin proteins were detected by immunoblot as in A.
- Fig. 2 Silibinin does not affect the degradation of the HIF-1 ⁇ protein or the expression of the HIF-1 ⁇ mRNA.
- A HeLa cells were exposed to hypoxia (2% O2) for 2 h, and silibinin (500 ⁇ mol / L) or the vehicle (control) were added 15 min before the end of the hypoxic incubation. The cells were then exposed to normoxia (reoxygenation) for the indicated periods, and the levels of the HIF-1 ⁇ protein were measured by immunoblot.
- the lower panel shows the densitometric quantification of the levels of HIF-1 ⁇ , with the values expressed as the percentage of the expression before reoxygenation (time 0). The values represent the mean ⁇ SE of four independent experiments.
- HIF-1 ⁇ CH13 KaO cells deficient in HIF-1 ⁇ were transfected with the wild type HIF-1 ⁇ , the mutant P402A / P564A-HIF-1 ⁇ or with the empty vector as described in Materials and Methods. After 24 h, the cells were exposed to normoxia or hypoxia (2% O 2 ) for 4 h in the presence of the indicated concentrations of silibinin (SiIi), and the recombinant HIF-1 ⁇ was detected by immunoblot.
- C HeLa cells were cultured under normoxic (21% O 2 ) or hypoxic (2% O2) conditions in the absence or presence of silibinin (500 ⁇ mol / L) for the indicated times.
- D Upper panel, HeLa cells were incubated for 2 h under normoxic conditions (21% O 2 ) or hypoxic (2% O 2 ). The cells were then treated for an additional hour under the same atmospheres in the presence of MG132 (20 ⁇ mol / L), cyclohexamide (CHX, 100 ⁇ mol / L) or silibinin (500 ⁇ mol / L), followed by immunoblot analysis.
- Lower panel HeLa cells were incubated for 3 h in hypoxia (2% O 2 ). Subsequently, the cells were treated in hypoxia for the additional times indicated with the vehicle (control), CHX (100 ⁇ mol / L) or silibinin (500 ⁇ mol / L), and HIF-1 ⁇ was detected by immunoblot.
- Fig. 3 Silibinin inhibits mTOR signaling and increases the phosphorylation of Akt in HeLa and Hep3B cancer cells.
- A The cells were incubated in hypoxia (2% O 2 ) for 3 h in the presence of the indicated concentrations of silibinin (SiIi). Lane 1 of each panel shows the baseline levels in normoxia of the proteins under study.
- B HeLa cells were incubated for 4 h in normoxia (21% O2) or hypoxia (2% O 2 ) in the presence of silibinin (500 ⁇ mol / L), LY294002 (LY, 10 ⁇ mol / L), or rapamycin ( Rapa, 20 nmol / L) as indicated.
- Hep3B cells were incubated as in B, and treated with the indicated concentrations of silibinin (SiIi) in the absence or presence of LY294002 (LY, 10 ⁇ mol / L).
- the proteins in AC were detected by immunoblot using the specific antibodies described in Materials and Methods.
- Fig. 4 The effects of silibinin on the mTOR pathway, the activation of Akt and the accumulation of HIF-1 ⁇ are rapid and completely reversible.
- HeLa and Hep3B cells were exposed to hypoxia (2% O 2 ) for 3 h, and silibinin (SiIi, 500 ⁇ mol / L) was added during the last 0 (untreated), 10, 20, 30 or 60 minutes of hypoxic incubation.
- Lanes 7 and 8 of each panel represent the cells treated with silibinin during the last 60 min of hypoxic incubation, followed by two washes of the extracellular medium to eliminate the silibinin, and the incubation for an additional period of 30 or 60 min under hypoxia. study the reversibility of the effects.
- Lane 1 of each panel shows the baseline normoxia levels of the analyzed proteins, which were detected by immunoblot.
- Fig. 5 Silibinin inhibits the release of hypoxia-induced VEGF in tumor cells HeLa and Hep3B.
- A The cells were incubated for 12 h in normoxia or hypoxia (2% O2) in the presence of the indicated silibinin concentration, and the extracellular medium was recovered for the determination of VEGF by ELISA as described in Materials and Methods. The values represent the mean ⁇ SE from three independent experiments. ** , P ⁇ 0.01, *** , P ⁇ 0.001, significantly different compared to control cells in hypoxia without silibinin.
- VEGF vascular endothelial growth factor
- Fig. 6 Effect of silibinin on the proliferation and apoptosis of HeLa and Hep3B tumor cells.
- A The cells were incubated in hypoxia (2% O2) with increasing concentrations of silibinin (0, 50, 100,
- Viable cells were quantified fluorimetrically by converting resazurin to resorufin, as described in Materials and Methods.
- B The cells were incubated for 8 h as in A, and apoptosis was quantified by measuring caspase-3 and -7 activities with a luminescent analysis, using staurosporin as a positive control (Staur, 500 nmol / L). The bars represent the mean ⁇ SE. * , P ⁇ 0.05, ** , P ⁇ 0.01, *** , P ⁇ 0.001, significantly different compared to the untreated control at each time.
- Fig. 7 Effect of silibinin on the signaling of mTOR and the phosphorylation of Akt in the AGS cell line of gastrointestinal cancer.
- AGS cells were cultured in hypoxia (2% O 2 ) for 3 h in the presence of the indicated concentrations of silibinin (SiIi). Lane 1 shows the baseline levels in normoxia of the proteins under study. The proteins indicated were detected by immunoblot using the specific antibodies described in Materials and Methods.
- Fig. 8 Effect of silibinin on the signaling of mTOR and the phosphorylation of Akt in the PC-3 cell line of prostate cancer.
- the PC-3 cells were cultured in hypoxia (1.5% O2) for 3 h in the presence of the indicated concentrations of silibinin (SiIi).
- Lane 1 shows the baseline levels in normoxia of the proteins under study.
- the proteins indicated were detected by immunoblot using the specific antibodies described in Materials and Methods.
- Fig. 9 Silibinin rapidly decreases the accumulation of the HIF-1 ⁇ protein under hypoxia despite the inhibition of proteosomal degradation of the protein.
- HeLa cells were exposed to hypoxia (2% O2) for 2 hours. Subsequently, the cells were treated for an additional hour in the same atmosphere, in the presence or absence of MG132 (20 ⁇ M), and silibilin (SiIi, 500 ⁇ M) or a vehicle was added for the last 0 (untreated), 10, 20, 30 or 60 minutes of hypoxic incubation. HIF-1 ⁇ and Actin were detected by western blot analysis.
- Fig. 10 Silibilin affects mTOR signaling and Akt forphosphorylation in HeLa and Hep3B cancer cells under normoxic conditions.
- the cells were cultured in normoxia (21% O2) for 3 hours in the presence of the indicated concentrations of silibinin (sili).
- silibinin SiIi, 500 ⁇ M was added for the last 0 (untreated), 10, 20, 30 or 60 minutes of incubation.
- Lanes 6 and 7 of each panel represent the cells treated with silibinin during the last 60 minutes of incubation followed by two washes of the extracellular medium to remove the silibinin, and the additional incubation for 30 or 60 minutes to study the reversibility of the effects. After the treatments, the indicated proteins were detected by western blot analysis in the complete cell extracts.
- Fig. 11 The TSC1 / TSC2 complex is necessary for the Akt-induced phosphorylation (Ser 473 ) but not for the mTOR / p70S6K / 4E- suppression.
- BP1 HeLa cells were transfected with TSC2 or control siRNA. 48 hours after transfection, the cells were treated for 3 hours in normoxia (21% O2) with the indicated concentrations of silibinin (SiIi), rapamycin (Rapa, 2OnM) or the vehicle. The cells were subsequently collected and a western blot analysis was performed to detect the indicated proteins,
- Fig. 12 Effect of silibinin and rapamycin on the proliferation of non-tumor epithelial cells.
- Primary fibroblasts of adult human skin and human embryonic renal cells (HEK293) were cultured in hypoxia (2% O 2 ) with increasing concentrations of silibinin (50, 100, 250, 500 ⁇ M) or rapamycin (1, 10, 100 nM) for 8 hours
- the fluorometrically viable cells were quantified as described in the materials and methods.
- the bars represent the mean ⁇ SE. * , P ⁇ 0.05, ** , P ⁇ 0.01, *** , P ⁇ 0.001, significantly different compared to untreated controls.
- HeLa Human cervical adenocarcinoma
- Hep3B hepatocellular carcinoma
- ATCC American Type Culture Collection
- DMEM fetal calf serum
- CHO Ka13.5 cells deficient in HIF-1 ⁇ were grown in a Ham's F-12 nutritive mixture (Invitrogen, Bacelona, Spain). Culture media were supplemented with 10% inactivated FBS (Sigma) and penicillin (100 IU / ml) / streptomycin (100 .mu.g / ml), and the cells were grown at 37 0 C in humidified incubator containing 5% CO2.
- a humidified hypoxia chamber COY Labs., Grasslake, Ml
- O2 regulator Air-Liquide, Madrid, Spain
- All cell treatments were carried out in a growth medium containing 3% FBS and without antibiotics.
- Silibinin, cyclohexamide, staurosporine and Z-Leu-Leu-Leu-al (MG132) were purchased from Sigma.
- Dimethyloxalyl glycine (DMOG) was purchased from Alexis Biochemicals (Lausen, Switzerland).
- HIF-1 ⁇ and HIF-1 ⁇ were from BD Transduction Laboratories (BD Biosciences, Madrid, Spain).
- LY294002 rapamycin and antibodies against phospho-Akt (Ser473), phospho-mTOR (Ser2448), phospho-p70S6 kinase (Thr389), phospho-ribosomal protein S6 (Ser235 / 236) and phospho-4E-BP1 (Ser65) CeII Signaling Technology (Beverly, MA).
- Anti- actin was obtained from Sigma.
- the cells were seeded in 60 mm culture plates and allowed to adhere for 24 hours. Immediately after the treatments, the cells were washed with cold PBS and recovered by scraping in 1-ml of cold PBS supplemented with a protease inhibitor cocktail (Roche Diagnostics, Barcelona, Spain). The cell pellets were homogenized in 50 ⁇ l of lysis buffer composed of a CytoBuster TM protein extraction reagent (Novagen) supplemented with protease inhibitor cocktails (Roche) and phosphatases (Sigma). After incubation on ice (15 min), the used ones were stirred and centrifuged (16,000 xg, 10 min, 4 ° C), and the supernatants collected as total cell extracts.
- lysis buffer composed of a CytoBuster TM protein extraction reagent (Novagen) supplemented with protease inhibitor cocktails (Roche) and phosphatases (Sigma). After incubation on ice (15 min), the used ones were stirred and centrifuged (16,000 xg,
- the protein concentration was determined by the BCA protein assay (Pierce). Cell extracts (40-80 ⁇ g of proteins) were separated by SDS-PAGE and transferred to nitrocellulose membranes, and the immunoblot was carried out as previously described. When required, the intensity of the bands was quantified with the Quantity One v4.6 software (Bio-Rad, Hercules, CA).
- HIF-1 ⁇ cDNA GenBank accession U22431; SEQ ID NO: 1
- ATCC accession U22431
- SEQ ID NO: 1 The human HIF-1 ⁇ cDNA was obtained from the ATCC (pCEP4 / HIF-1 ⁇ ).
- pcDNA4 / HisMax The primers were designed to contain the restriction sites for Bam ⁇ ⁇ ⁇ and Not ⁇ at terminations 5 ' and 3 ' , respectively.
- Primers SEQ ID NO: 2 and SEQ ID NO: 3 were used.
- the amplified PCR product was purified (QIAquick PCR Purification Kit, Qiagen, Valencia, CA), digested with Bam ⁇ ⁇ ⁇ and Not ⁇ , and ligated into pcDNA4 / HisMax previously digested with the same restriction enzymes.
- the resulting construct, pcDNA4 / HisMax-HIF-1 ⁇ was amplified and purified (Qiagen).
- the double mutant HIF-1 ⁇ P402A / P564A was generated by sequentially directed mutagenesis (QuickChange II, Stratagene) using as a pattern pcDNA4 / HisMax-HIF-1 ⁇ .
- the mutagenic oligonucleotides were, for the P402A mutation SEQ ID NO: 4 and SEQ ID NO: 5; for the P564A mutation, SEQ ID NO: 6 and SEQ ID NO: 7).
- This mutant of HIF-1 ⁇ is not susceptible to hydroxylation by prolyl-4-hydroxylases and subsequent degradation.
- the uncertainty of the cons ⁇ rucations was confirmed by DNA sequencing.
- Transient transfection and reporter trial of HRE-dependent luciferase Transffective transfection of CHO Ka13.5 cells was carried out in 60 mm culinary plates using Lipofec ⁇ amine2000 (Invitrogen) and 1 ⁇ g of the DNA plasmid (wild type HIF-1 ⁇ , P402A / P564A-HIF-1 ⁇ , or the empty vector).
- the cells were cultured in 24-well plates and transfected with 0.3 ⁇ g per well of the reporter plasmid p9HIF1-Luc using the transfection agent FuGENE 6 (Roche) according to the manufacturer's instructions.
- the transfection efficiency was monitored by cotransfection with 0.1 ⁇ g of the control plasmid pRL-TK (Promega) carrying the Renilla luciferase gene.
- the activities of firefly and Renilla luciferase were tested using the Dual-Glo Luciferase Assay System (Promega), and the firefly luciferase activity was normalized to the activity of Renilla luciferase.
- VEGF quantification The concentration of human VEGF in the conditioned cell medium was measured with an ELISA kit (Pierce). The cells were seeded in 6-well plates and cultured to reach 80-90% confluence. The medium was replaced and the cultures were treated as indicated. The secreted VEGF was quantified after 12 h in the extracellular medium (50 ⁇ l). The results were normalized with respect to the amount of total protein per well.
- the PCR conditions were established in pilot experiments to ensure the linearity of reaction rates GAPDH was used as the internal standard.
- the PCR products were separated on 1.5% agarose gels and visualized by staining with ethidium bromide. The gels were photographed using an image analyzer GeI DOC 2000 (Bio-Rad).
- Cell proliferation and apoptosis were studied with the Cell-Blue® CeII Viability Assay fluorimetric assay (Promega), which exploits the ability of the resazurin indicator to measure the metabolic capacity, an indication of cell viability.
- Cell-Blue® CeII Viability Assay fluorimetric assay Promega
- Caspase-Glo® 3/7 Assay luminescent assay Promega
- EXAMPLE 1 Silibinin inhibits the accumulation of hypoxia-induced HIF-1 ⁇ in tumor cells HeLa and Hep3B.
- hypoxia induced a time-dependent accumulation of HIF-1 ⁇ protein in HeLa and Hep3B tumor cells that was noticeable after 1 h.
- Silibinin inhibited the accumulation of HIF-1 ⁇ (Fig. 1A), and this inhibition was complete within the first hour of treatment with silibinin in both cell types, and persisted while the drug was present in the medium (at least up to 16 h , data not revealed).
- silibinin did not alter the levels of HIF-1 ⁇ protein (Fig. 1A).
- silibinin fully advocated the accumulation of HIF-1 ⁇ induced by the DMOG inhibitor (Fig. 1 B), a well-characterized mimetic hypoxic agent. Consistent with the inhibition of the accumulation of HIF-1 ⁇ , silibinin also produced the dose-dependent inhibition of the transcriptional activity of HIF-1 in cells exposed to hypoxia or treated with DMOG, as determined using a reporter construct of the response to hypoxia (Fig. 1C).
- HIF-1 ⁇ did not stabilize at O2 concentrations of 6%, with accumulation increasing markedly as the
- Silibinin does not affect the stability of HIF-1 ⁇ or its degradation mediated by prolyl hydroxylases.
- HIF-1 ⁇ is mainly degraded by the ubiquitin / proteasome system after Ia hydroxylation of prolines 402 and 564 by the specific prolyl hydroxylases of HIF-1 ⁇ .
- various experimental strategies were employed. First, reoxygenation experiments were performed. The cells were exposed to hypoxia, and the silibinin or vehicle was added during the last 15 minutes of hypoxic incubation.
- the MG132 proteasome inhibitor was used to prevent ubiquitin-dependent degradation of HIF-1 ⁇ .
- the treatment of cells with MG132 resulted in a pronounced accumulation of high molecular weight protein species of HIF-1 ⁇ - ubiquitinated, in normoxia and in hypoxia (the upper panel of Fig. 2.a, lanes 2 and 6).
- the inhibition of protein synthesis with cyclohexamide totally prevented the accumulation of ubiquitinated HIF-1 ⁇ in the presence of MG132 (lanes 3 and 7).
- EXAMPLE 4 The inhibition of the translation of the HIF-1 ⁇ protein by silibinin implies the repression of mTOR and its effectors p70S6K, rpS6 and 4E-BP1.
- the PI3K / Akt / mTOR pathway has been implicated in the regulation of the expression of the HIF-1 ⁇ protein, predominantly at the level of its translation.
- hypoxia causes dephosphorylation and repression of mTOR, resulting in a decrease in the synthesis rate of HIF-1 ⁇ .
- silibinin inhibits the synthesis of HIF-1 ⁇ protein in hypoxia through the regulation of the mTOR / p70S6K / 4E-BP1 pathway
- the treatment of HeLa and Hep3B cells with silibinin under hypoxic conditions produced a dose-dependent dephosphorylation of mTOR in Ser 2448 , which was correlated with the inhibition of phosphorylation of p70S6K, rpS6 and 4E-BP1, and with the reduction of the accumulation of HIF-1 ⁇ in both types of tumor cell lines (Fig. 3A).
- the level of p-Akt in HeLa cells was increased after exposure to silibinin for 20 minutes (500 ⁇ mol / L), while decreasing below baseline levels in Hep3B cells.
- the inhibition of the accumulation of HIF-1 ⁇ was reversed rapidly after two changes of the medium to eliminate silibinin from the cells. This reversal was evident after 30 minutes and was complete after 60 minutes under the same hypoxic atmosphere (Fig. 4, lanes 7 and 8).
- all the phospho-proteins analyzed returned to their basic phosphorylation levels.
- Silibinin inhibits hypoxia-induced secretion of VEGF in tumor cells. Silibinin has demonstrated anti-angiogenic characteristics in several experimental models. Since HIF-1 is the main regulator of VEGF in hypoxia, the effect of silibinin on the production of VEGF in vitro was analyzed. Compared to normoxia, exposure of HeLa or Hep3B cells to hypoxia for 12 h produced a 2-3-fold increase in VEGF secretion to the extracellular medium.
- PI3K / Akt LY294002 inhibitor 10 ⁇ mol / L
- the PI3K / Akt LY294002 inhibitor produced an inhibition of the release of VEGF (-30%) similar to that induced by a submaximal dose of silibinin (250 ⁇ mol / L)
- the mTOR inhibitor Rapamycin (20 nmol / L) produced a weak inhibition of -15% (Fig. 5B).
- the combined treatment with these doses of silibinin and LY294002 resulted in a synergistic effect, reducing the release of VEGF near the control levels in normoxia.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne l'utilisation d'une composition qui comprend de la silibinine dans une proportion nécessaire pour atteindre des concentrations en sérum supérieures ou égales à 250 μM, ou dans une variante, de la silibinine et un inhibiteur de Akt, pour l'élaboration d'un médicament destiné au traitement du cancer, et une préparation combinée au moins de silibinine et d'un inhibiteur de la voie PI3K/Akt, pour son utilisation séparée, simultanée ou séquentielle dans le traitement du cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200802800A ES2345587B1 (es) | 2008-10-02 | 2008-10-02 | Composicion que comprende silibinin y un inhibidor de la via p13k/aktpara el tratamiento del cancer. |
ESP200802800 | 2008-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010037892A1 true WO2010037892A1 (fr) | 2010-04-08 |
Family
ID=42073025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2009/070415 WO2010037892A1 (fr) | 2008-10-02 | 2009-10-02 | Composition comprenant de la silibinine à des concentrations déterminées et préparation combinée comprenant de la silibinine et un inhibiteur de la voie pi3k/akt pour le traitement du cancer |
Country Status (2)
Country | Link |
---|---|
ES (1) | ES2345587B1 (fr) |
WO (1) | WO2010037892A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102942551A (zh) * | 2012-12-04 | 2013-02-27 | 贵阳医学院 | 含有3-硝基丙酰基的黄烷醇和含其的药物组合物及其在制药中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003090741A1 (fr) * | 2001-04-07 | 2003-11-06 | Zielinski Jan E | Proformes hydrophiles et lipophiles de la silibinine et leur application |
-
2008
- 2008-10-02 ES ES200802800A patent/ES2345587B1/es not_active Withdrawn - After Issue
-
2009
- 2009-10-02 WO PCT/ES2009/070415 patent/WO2010037892A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003090741A1 (fr) * | 2001-04-07 | 2003-11-06 | Zielinski Jan E | Proformes hydrophiles et lipophiles de la silibinine et leur application |
Non-Patent Citations (6)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102942551A (zh) * | 2012-12-04 | 2013-02-27 | 贵阳医学院 | 含有3-硝基丙酰基的黄烷醇和含其的药物组合物及其在制药中的应用 |
Also Published As
Publication number | Publication date |
---|---|
ES2345587A1 (es) | 2010-09-27 |
ES2345587B1 (es) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2609767T3 (es) | Combinaciones de un inhibidor de PI3K y un inhibidor de MEK | |
Kéri et al. | A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. | |
AU2005300727B2 (en) | Use of Pirlindole for the treatment of diseases which are characterized by proliferation of T-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis | |
Pan et al. | Nitidine chloride inhibits breast cancer cells migration and invasion by suppressing c-Src/FAK associated signaling pathway | |
Yang et al. | A novel PTP1B inhibitor extracted from Ganoderma lucidum ameliorates insulin resistance by regulating IRS1-GLUT4 cascades in the insulin signaling pathway | |
ES2733929T3 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
JP2017160258A (ja) | 代謝経路を変調させるための組成物および方法 | |
Cherrin et al. | An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo | |
AU2014244053B2 (en) | Treatment of a diastolic cardiac dysfunction with a TRPV2 receptor agonist | |
ES2901712T3 (es) | Combinación de un inhibidor de pi3k y un inhibidor de c-met. | |
NO330756B1 (no) | N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasoytisk akseptabelt salt av denne, til behandling av kreft | |
Lee et al. | Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms | |
Yu et al. | AMPK activation by ozone therapy inhibits tissue factor-triggered intestinal ischemia and ameliorates chemotherapeutic enteritis | |
ES2289316T3 (es) | Tratamiento terapeutico. | |
ES2754034T3 (es) | Combinación para el tratamiento de cáncer | |
ES2345587B1 (es) | Composicion que comprende silibinin y un inhibidor de la via p13k/aktpara el tratamiento del cancer. | |
TWI733026B (zh) | 昭和草萃取物於治療乳癌之用途 | |
JP2016520662A (ja) | Pi3k阻害剤および微小管不安定化剤の医薬組み合わせ | |
CN104902901A (zh) | 使用cbp/连环蛋白的抑制剂治疗过度增殖性和癌前皮肤病 | |
MXPA06003056A (es) | Tratamiento de tumores estromales gastrointestinales con imatinib y midostaurin. | |
KR102236686B1 (ko) | 2-(3-[2-(1-시클로헥센-1-일)에틸]-6,7-디메톡시-4-옥소-3,4-디히드로-2-퀴나졸리닐술파닐)-n-(4-에틸페닐)부탄아미드를 유효성분으로 포함하는 암 치료 또는 예방용 조성물 | |
JP2019505536A (ja) | 肥満の処置のための方法及び医薬組成物 | |
US11376247B2 (en) | Tyrosine kinase inhibitors regenerate non-cancerous tissue after cancer therapy | |
WO2021053618A1 (fr) | Traitement comprenant des agonistes de fxr | |
KR20240041259A (ko) | 종양 혈관 파괴용 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09817324 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09817324 Country of ref document: EP Kind code of ref document: A1 |